Orthovita Touts Cortoss As Alternative To Cement For Vertebral Fractures
This article was originally published in The Gray Sheet
Executive Summary
Orthovita aims to position its Cortoss bone augmentation material as a favorable alternative to polymethylmethacrylate (PMMA) cement for treatment of vertebral compression fractures when it launches the device in July
You may also be interested in...
Struggling Orthovita Taps Distributors To Chase Outpatient Vertebroplasties
A rapid shift of minimally invasive procedures for vertebrae fractures to the outpatient setting is weighing down Orthovita's growth prospects, but the firm says it plans to leverage external distributors to counteract some of the pressure
Struggling Orthovita Taps Distributors To Chase Outpatient Vertebroplasties
A rapid shift of minimally invasive procedures for vertebrae fractures to the outpatient setting is weighing down Orthovita's growth prospects, but the firm says it plans to leverage external distributors to counteract some of the pressure
Wells Fargo Healthcare Conference In Brief
Orthovita: The company is in discussions with FDA regarding a 510(k) for a next-generation Vitoss bone graft substitute; it hopes to launch the device in the first quarter of 2011, Chief Financial Officer Nancy Broadbent said during a June 23 presentation at the Wells Fargo Healthcare Conference in Boston. The device will incorporate a drug that has "demonstrated positive impact on bone regeneration," she noted. Orthovita also plans to study new indications for Cortoss bone augmentation material, which was cleared last year for vertebral compression fractures, but Broadbent declined to be specific (1"The Gray Sheet" June 15, 2009). She explained that the company decided to lower the average selling price of Cortoss from $2,000 to $1,300 after the launch to better compete with existing vertebroplasty products, which cost about $950, she noted. "Our accounts have [since] grown steadily every month," she claimed